Single User License
INR 170050
Site License
INR 340100
Corporate User License
INR 510150

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Liver Cancer-Pipeline Review, H1 2015

Liver Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Liver Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Liver Cancer-Pipeline Review, H1 2015', provides an overview of the Liver Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Liver Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Liver Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 9

Liver Cancer Overview 10

Therapeutics Development 11

Liver Cancer-Therapeutics under Development by Companies 13

Liver Cancer-Therapeutics under Investigation by Universities/Institutes 26

Liver Cancer-Pipeline Products Glance 30

Liver Cancer-Products under Development by Companies 33

Liver Cancer-Products under Investigation by Universities/Institutes 50

Liver Cancer-Companies Involved in Therapeutics Development 53

Liver Cancer-Therapeutics Assessment 198

Drug Profiles 219

Liver Cancer-Recent Pipeline Updates 656

Liver Cancer-Dormant Projects 928

Liver Cancer-Discontinued Products 942

Liver Cancer-Product Development Milestones 946

Appendix 953

List of Tables

Number of Products under Development for Liver Cancer, H1 2015 39

Number of Products under Development for Liver Cancer-Comparative Analysis, H1 2015 40

Number of Products under Development by Companies, H1 2015 42

Number of Products under Development by Companies, H1 2015 (Contd..1) 43

Number of Products under Development by Companies, H1 2015 (Contd..2) 44

Number of Products under Development by Companies, H1 2015 (Contd..3) 45

Number of Products under Development by Companies, H1 2015 (Contd..4) 46

Number of Products under Development by Companies, H1 2015 (Contd..5) 47

Number of Products under Development by Companies, H1 2015 (Contd..6) 48

Number of Products under Development by Companies, H1 2015 (Contd..7) 49

Number of Products under Development by Companies, H1 2015 (Contd..8) 50

Number of Products under Development by Companies, H1 2015 (Contd..9) 51

Number of Products under Development by Companies, H1 2015 (Contd..10) 52

Number of Products under Development by Companies, H1 2015 (Contd..11) 53

Number of Products under Investigation by Universities/Institutes, H1 2015 54

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 56

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 57

Comparative Analysis by Late Stage Development, H1 2015 58

Comparative Analysis by Clinical Stage Development, H1 2015 59

Comparative Analysis by Early Stage Development, H1 2015 60

Products under Development by Companies, H1 2015 61

Products under Development by Companies, H1 2015 (Contd..1) 62

Products under Development by Companies, H1 2015 (Contd..2) 63

Products under Development by Companies, H1 2015 (Contd..3) 64

Products under Development by Companies, H1 2015 (Contd..4) 65

Products under Development by Companies, H1 2015 (Contd..5) 66

Products under Development by Companies, H1 2015 (Contd..6) 67

Products under Development by Companies, H1 2015 (Contd..7) 68

Products under Development by Companies, H1 2015 (Contd..8) 69

Products under Development by Companies, H1 2015 (Contd..9) 70

Products under Development by Companies, H1 2015 (Contd..10) 71

Products under Development by Companies, H1 2015 (Contd..11) 72

Products under Development by Companies, H1 2015 (Contd..12) 73

Products under Development by Companies, H1 2015 (Contd..13) 74

Products under Development by Companies, H1 2015 (Contd..14) 75

Products under Development by Companies, H1 2015 (Contd..15) 76

Products under Development by Companies, H1 2015 (Contd..16) 77

Products under Investigation by Universities/Institutes, H1 2015 78

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 79

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 80

Liver Cancer-Pipeline by 4SC AG, H1 2015 81

Liver Cancer-Pipeline by AB Science, H1 2015 82

Liver Cancer-Pipeline by AbbVie Inc., H1 2015 83

Liver Cancer-Pipeline by Acceleron Pharma, Inc., H1 2015 84

Liver Cancer-Pipeline by Active Biotech AB, H1 2015 85

Liver Cancer-Pipeline by Adaptimmune Limited, H1 2015 86

Liver Cancer-Pipeline by Aduro BioTech, Inc., H1 2015 87

Liver Cancer-Pipeline by Advanced Accelerator Applications SA, H1 2015 88

Liver Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 89

Liver Cancer-Pipeline by Alfact Innovation, H1 2015 90

Liver Cancer-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 91

Liver Cancer-Pipeline by American Gene Technologies International Inc., H1 2015 92

Liver Cancer-Pipeline by Amgen Inc., H1 2015 93

Liver Cancer-Pipeline by AndroScience Corporation, H1 2015 94

Liver Cancer-Pipeline by APAvadis Biotechnologies Srl, H1 2015 95

Liver Cancer-Pipeline by ArQule, Inc., H1 2015 96

Liver Cancer-Pipeline by Array BioPharma Inc., H1 2015 97

Liver Cancer-Pipeline by Arrowhead Research Corporation, H1 2015 98

Liver Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 99

Liver Cancer-Pipeline by AstraZeneca Plc, H1 2015 100

Liver Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 101

Liver Cancer-Pipeline by Bayer AG, H1 2015 102

Liver Cancer-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 103

Liver Cancer-Pipeline by BioCancell Ltd, H1 2015 104

Liver Cancer-Pipeline by Bioncotech Therapeutics S.L., H1 2015 105

Liver Cancer-Pipeline by Bioneer Corporation, H1 2015 106

Liver Cancer-Pipeline by BioStar Pharmaceuticals, Inc., H1 2015 107

Liver Cancer-Pipeline by Blueprint Medicines, H1 2015 108

Liver Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 109

Liver Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 110

Liver Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 111

Liver Cancer-Pipeline by Caladrius Biosciences, Inc. , H1 2015 112

Liver Cancer-Pipeline by Can-Fite BioPharma Ltd., H1 2015 113

Liver Cancer-Pipeline by CASI Pharmaceuticals Inc., H1 2015 114

Liver Cancer-Pipeline by CCRP Therapeutics GmbH, H1 2015 115

Liver Cancer-Pipeline by Celgene Corporation, H1 2015 116

Liver Cancer-Pipeline by Celsion Corporation, H1 2015 117

Liver Cancer-Pipeline by China Medical System Holdings Limited, H1 2015 118

Liver Cancer-Pipeline by Chipscreen Biosciences Ltd, H1 2015 119

Liver Cancer-Pipeline by Chroma Therapeutics Limited, H1 2015 120

Liver Cancer-Pipeline by CrystalGenomics, Inc., H1 2015 121

Liver Cancer-Pipeline by CytRx Corporation, H1 2015 122

Liver Cancer-Pipeline by CZ BioMed Corp, H1 2015 123

Liver Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 124

Liver Cancer-Pipeline by Delcath Systems, Inc., H1 2015 125

Liver Cancer-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 126

Liver Cancer-Pipeline by Digna Biotech, S.L., H1 2015 127

Liver Cancer-Pipeline by e-Therapeutics Plc, H1 2015 128

Liver Cancer-Pipeline by Eisai Co., Ltd., H1 2015 129

Liver Cancer-Pipeline by Eli Lilly and Company, H1 2015 130

Liver Cancer-Pipeline by Endocyte, Inc., H1 2015 131

Liver Cancer-Pipeline by Exelixis, Inc., H1 2015 132

Liver Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 133

Liver Cancer-Pipeline by Gamida Cell Ltd., H1 2015 134

Liver Cancer-Pipeline by Genelux Corporation, H1 2015 135

Liver Cancer-Pipeline by Genoscience Pharma, H1 2015 136

Liver Cancer-Pipeline by GenSpera, Inc., H1 2015 137

Liver Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 138

Liver Cancer-Pipeline by Gradalis Inc., H1 2015 139

Liver Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 140

Liver Cancer-Pipeline by Immune Network, Ltd., H1 2015 141

Liver Cancer-Pipeline by Immunicum AB, H1 2015 142

Liver Cancer-Pipeline by Immunitor, Inc., H1 2015 143

Liver Cancer-Pipeline by Immunomedics, Inc., H1 2015 144

Liver Cancer-Pipeline by Immunovative Therapies, Ltd., H1 2015 145

Liver Cancer-Pipeline by Immuron Limited, H1 2015 146

Liver Cancer-Pipeline by IMPACT Therapeutics, Inc., H1 2015 147

Liver Cancer-Pipeline by In Cell Art, H1 2015 148

Liver Cancer-Pipeline by Incuron, LLC, H1 2015 149

Liver Cancer-Pipeline by Intezyne, Inc, H1 2015 150

Liver Cancer-Pipeline by Jasco Pharmaceuticals, LLC., H1 2015 151

Liver Cancer-Pipeline by Johnson & Johnson, H1 2015 152

Liver Cancer-Pipeline by KAHR medical Ltd., H1 2015 153

Liver Cancer-Pipeline by Keystone Nano, Inc., H1 2015 154

Liver Cancer-Pipeline by Komipharm International Co., Ltd., H1 2015 155

Liver Cancer-Pipeline by Kowa Company, Ltd., H1 2015 156

Liver Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 157

Liver Cancer-Pipeline by Les Laboratoires Servier SAS, H1 2015 158

Liver Cancer-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 159

Liver Cancer-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 160

Liver Cancer-Pipeline by Lytix Biopharma AS, H1 2015 161

Liver Cancer-Pipeline by MaxCyte, Inc., H1 2015 162

Liver Cancer-Pipeline by MedImmune, LLC, H1 2015 163

Liver Cancer-Pipeline by Medivation, Inc., H1 2015 164

Liver Cancer-Pipeline by Merck KGaA, H1 2015 165

Liver Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 166

Liver Cancer-Pipeline by Mirna Therapeutics, Inc., H1 2015 167

Liver Cancer-Pipeline by MolMed S.p.A., H1 2015 168

Liver Cancer-Pipeline by MultiCell Technologies, Inc., H1 2015 169

Liver Cancer-Pipeline by Nanobiotix, H1 2015 170

Liver Cancer-Pipeline by NeoPharm Co., Ltd., H1 2015 171

Liver Cancer-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 172

Liver Cancer-Pipeline by Nimbus Therapeutics, LLC, H1 2015 173

Liver Cancer-Pipeline by Northwest Biotherapeutics, Inc., H1 2015 174

Liver Cancer-Pipeline by Novartis AG, H1 2015 175

Liver Cancer-Pipeline by Nymox Pharmaceutical Corporation, H1 2015 176

Liver Cancer-Pipeline by Omeros Corporation, H1 2015 177

Liver Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2015 178

Liver Cancer-Pipeline by Oncology Research International Limited, H1 2015 179

Liver Cancer-Pipeline by Oncolys BioPharma Inc., H1 2015 180

Liver Cancer-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 181

Liver Cancer-Pipeline by OncoTherapy Science, Inc., H1 2015 182

Liver Cancer-Pipeline by Oncothyreon Inc., H1 2015 183

Liver Cancer-Pipeline by Oneness Biotech Co., Ltd., H1 2015 184

Liver Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 185

Liver Cancer-Pipeline by Onxeo SA, H1 2015 186

Liver Cancer-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 187

Liver Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 188

Liver Cancer-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 189

Liver Cancer-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 190

Liver Cancer-Pipeline by Pfizer Inc., H1 2015 191

Liver Cancer-Pipeline by Pharma Mar, S.A., H1 2015 192

Liver Cancer-Pipeline by PharmAbcine, Inc., H1 2015 193

Liver Cancer-Pipeline by PhaseRx, Inc., H1 2015 194

Liver Cancer-Pipeline by Phosplatin Therapeutics LLC, H1 2015 195

Liver Cancer-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 196

Liver Cancer-Pipeline by Priaxon AG, H1 2015 197

Liver Cancer-Pipeline by Progen Pharmaceuticals Limited, H1 2015 198

Liver Cancer-Pipeline by ProMetic Life Sciences Inc., H1 2015 199

Liver Cancer-Pipeline by Provecs Medical GmbH, H1 2015 200

Liver Cancer-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 201

Liver Cancer-Pipeline by Qu Biologics Inc., H1 2015 202

Liver Cancer-Pipeline by Quimatryx, S.L., H1 2015 203

Liver Cancer-Pipeline by Raptor Pharmaceuticals Corp., H1 2015 204

Liver Cancer-Pipeline by Regulus Therapeutics Inc., H1 2015 205

Liver Cancer-Pipeline by Rigontec GmbH, H1 2015 206

Liver Cancer-Pipeline by Shenogen Pharma Group Ltd., H1 2015 207

Liver Cancer-Pipeline by Sirnaomics, Inc., H1 2015 208

Liver Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 209

Liver Cancer-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 210

Liver Cancer-Pipeline by Targetome, H1 2015 211

Liver Cancer-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 212

Liver Cancer-Pipeline by Therapure Biopharma Inc., H1 2015 213

Liver Cancer-Pipeline by Theravectys S.A., H1 2015 214

Liver Cancer-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 215

Liver Cancer-Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2015 216

Liver Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 217

Liver Cancer-Pipeline by Transgene Biotek Limited, H1 2015 218

Liver Cancer-Pipeline by VasGene Therapeutics, Inc., H1 2015 219

Liver Cancer-Pipeline by Vaxon Biotech, H1 2015 220

Liver Cancer-Pipeline by Vicus Therapeutics, LLC, H1 2015 221

Liver Cancer-Pipeline by Virttu Biologics Limited, H1 2015 222

Liver Cancer-Pipeline by Viventia Biotechnologies Inc., H1 2015 223

Liver Cancer-Pipeline by Welichem Biotech Inc., H1 2015 224

Liver Cancer-Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 225

Assessment by Monotherapy Products, H1 2015 226

Assessment by Combination Products, H1 2015 227

Number of Products by Stage and Target, H1 2015 229

Number of Products by Stage and Mechanism of Action, H1 2015 237

Number of Products by Stage and Route of Administration, H1 2015 244

Number of Products by Stage and Molecule Type, H1 2015 246

Liver Cancer Therapeutics-Recent Pipeline Updates, H1 2015 683

Liver Cancer-Dormant Projects, H1 2015 955

Liver Cancer-Dormant Projects (Contd..1), H1 2015 956

Liver Cancer-Dormant Projects (Contd..2), H1 2015 957

Liver Cancer-Dormant Projects (Contd..3), H1 2015 958

Liver Cancer-Dormant Projects (Contd..4), H1 2015 959

Liver Cancer-Dormant Projects (Contd..5), H1 2015 960

Liver Cancer-Dormant Projects (Contd..6), H1 2015 961

Liver Cancer-Dormant Projects (Contd..7), H1 2015 962

Liver Cancer-Dormant Projects (Contd..8), H1 2015 963

Liver Cancer-Dormant Projects (Contd..9), H1 2015 964

Liver Cancer-Dormant Projects (Contd..10), H1 2015 965

Liver Cancer-Dormant Projects (Contd..11), H1 2015 966

Liver Cancer-Dormant Projects (Contd..12), H1 2015 967

Liver Cancer-Dormant Projects (Contd..13), H1 2015 968

Liver Cancer-Discontinued Products, H1 2015 969

Liver Cancer-Discontinued Products (Contd..1), H1 2015 970

Liver Cancer-Discontinued Products (Contd..2), H1 2015 971

Liver Cancer-Discontinued Products (Contd..3), H1 2015 972

List of Figures

Number of Products under Development for Liver Cancer, H1 2015 39

Number of Products under Development for Liver Cancer-Comparative Analysis, H1 2015 40

Number of Products under Development by Companies, H1 2015 41

Number of Products under Investigation by Universities/Institutes, H1 2015 54

Comparative Analysis by Clinical Stage Development, H1 2015 59

Comparative Analysis by Early Stage Products, H1 2015 60

Assessment by Monotherapy Products, H1 2015 226

Assessment by Combination Products, H1 2015 227

Number of Products by Top 10 Targets, H1 2015 228

Number of Products by Stage and Top 10 Targets, H1 2015 228

Number of Products by Top 10 Mechanism of Actions, H1 2015 236

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 236

Number of Products by Top 10 Routes of Administration, H1 2015 243

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 243

Number of Products by Top 10 Molecule Types, H1 2015 245

Number of Products by Stage and Top 10 Molecule Types, H1 2015 245

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science

AbbVie Inc.

Acceleron Pharma, Inc.

Active Biotech AB

Adaptimmune Limited

Aduro BioTech, Inc.

Advanced Accelerator Applications SA

Advenchen Laboratories, LLC

Alfact Innovation

Alnylam Pharmaceuticals, Inc.

American Gene Technologies International Inc.

Amgen Inc.

AndroScience Corporation

APAvadis Biotechnologies Srl

ArQule, Inc.

Array BioPharma Inc.

Arrowhead Research Corporation

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

Bio-Cancer Treatment International Limited

BioCancell Ltd

Bioncotech Therapeutics S.L.

Bioneer Corporation

BioStar Pharmaceuticals, Inc.

Blueprint Medicines

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Caladrius Biosciences, Inc.

Can-Fite BioPharma Ltd.

CASI Pharmaceuticals Inc.

CCRP Therapeutics GmbH

Celgene Corporation

Celsion Corporation

China Medical System Holdings Limited

Chipscreen Biosciences Ltd

Chroma Therapeutics Limited

CrystalGenomics, Inc.

CytRx Corporation

CZ BioMed Corp

Daiichi Sankyo Company, Limited

Delcath Systems, Inc.

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

e-Therapeutics Plc

Eisai Co., Ltd.

Eli Lilly and Company

Endocyte, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Gamida Cell Ltd.

Genelux Corporation

Genoscience Pharma

GenSpera, Inc.

GlaxoSmithKline Plc

Gradalis Inc.

Hutchison MediPharma Limited

Immune Network, Ltd.

Immunicum AB

Immunitor, Inc.

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Immuron Limited

IMPACT Therapeutics, Inc.

In Cell Art

Incuron, LLC

Intezyne, Inc

Jasco Pharmaceuticals, LLC.

Johnson & Johnson

KAHR medical Ltd.

Keystone Nano, Inc.

Komipharm International Co., Ltd.

Kowa Company, Ltd.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

Ligand Pharmaceuticals, Inc.

Lixte Biotechnology Holdings, Inc.

Lytix Biopharma AS

MaxCyte, Inc.

MedImmune, LLC

Medivation, Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

MultiCell Technologies, Inc.

Nanobiotix

NeoPharm Co., Ltd.

Nerviano Medical Sciences S.r.l.

Nimbus Therapeutics, LLC

Northwest Biotherapeutics, Inc.

Novartis AG

Nymox Pharmaceutical Corporation

Omeros Corporation

Omnitura Therapeutics Inc.

Oncology Research International Limited

Oncolys BioPharma Inc.

OncoMed Pharmaceuticals, Inc.

OncoTherapy Science, Inc.

Oncothyreon Inc.

Oneness Biotech Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Onyx Pharmaceuticals, Inc.

Otsuka Holdings Co., Ltd.

Panacea Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharma Mar, S.A.

PharmAbcine, Inc.

PhaseRx, Inc.

Phosplatin Therapeutics LLC

Polaris Pharmaceuticals, Inc.

Priaxon AG

Progen Pharmaceuticals Limited

ProMetic Life Sciences Inc.

Provecs Medical GmbH

Provectus Biopharmaceuticals, Inc.

Qu Biologics Inc.

Quimatryx, S.L.

Raptor Pharmaceuticals Corp.

Regulus Therapeutics Inc.

Rigontec GmbH

Shenogen Pharma Group Ltd.

Sirnaomics, Inc.

Synta Pharmaceuticals Corp.

Taiwan Liposome Company, Ltd.

Targetome

Tekmira Pharmaceuticals Corp.

Therapure Biopharma Inc.

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

Toko Pharmaceutical Industries Co., Ltd.

TRACON Pharmaceuticals, Inc.

Transgene Biotek Limited

VasGene Therapeutics, Inc.

Vaxon Biotech

Vicus Therapeutics, LLC

Virttu Biologics Limited

Viventia Biotechnologies Inc.

Welichem Biotech Inc.

Zhejiang BetaPharma Co., Ltd.

Liver Cancer Therapeutic Products under Development, Key Players in Liver Cancer Therapeutics, Liver Cancer Pipeline Overview, Liver Cancer Pipeline, Liver Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com